Evidence map›Paper›PMID 40064754›Full record

ReviewDermatology and therapy2025

Chronic Hand Eczema (CHE): A Narrative Review.

Gioele Ghezzi, Costanza Falcidia, Giovanni Paolino, Santo R Mercuri, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

Abstract readReview
In one paragraph

Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gioele Ghezzi *Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Costanza Falcidia *Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Giovanni PaolinoUnit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy.
Santo R MercuriUnit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy.
Alessandra NarcisiDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Antonio CostanzoDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Mario ValentiDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. mario.valenti@hunimed.eu.ORCID http://orcid.org/0000-0001-9140-9263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent hand dermatitis which lasts over 3 months or recurs at least twice a year. This condition is often multifactorial, involving genetic predispositions, environmental factors and triggers, such as irritants and allergens. Studies show a higher incidence in women, though prevalence estimates vary across different age groups. The pathogenesis involves complex immune mechanisms, particularly Th1/Th2 cell responses. Clinically, CHE presents in various forms, with symptoms such as redness, scaling and itching that significantly impact patients' quality of life. Treatment approaches are diverse. While emollients and topical corticosteroids have historically been the mainstay, new systemic therapies like JAK inhibitors and biologics are progressively being used for severe cases. Key molecular targets comprise interleukin (IL)-4 and IL-13, the JAK-STAT pathway, phosphodiesterase 4 (PDE4) and chemoattractant chemokines. Managing CHE effectively remains a challenge because of its chronicity and the variability in individual responses to treatment. However, emerging therapeutic strategies will help clinicians to offer more patient-centred approaches.

Indexed as

Atopic dermatitisChronic hand eczemaHand dermatitisTherapeutics

Identifiers

PMID40064754
PMCPMC11971080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.